Additional targets being evaluated in recent clinical trials include a prostate-specific membrane antigen (PSMA) expressed over 100 times higher in prostate tumor tissues than normal prostate and the tumor differentiation antigen mesothelin in ovarian cancer [117, 118]. The gene discussed is FOLH1; the disease is ovarian carcinoma.